Chandler D. Robinson
Principal executive officer pay for Chandler D. Robinson, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Monopar Therapeutics (MNPR) FY2023–FY2025
Aligned: paid up as stock roseCAP -$166,177→$17,379,663 while $100 invested went $14.35→$3838.92
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $1.8M | -$166,177 |
| FY2024 | $1.1M | $2.4M |
| FY2025 | $10.6M | $17.4M |
The company's "$100 invested" index ran $14.35 at FY2023 → $3838.92 by FY2025 — an annualized return of 1535.6%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 1535.6%/yr at MNPR ( FY2023–FY2025). See the CEO track-record ranking for context.